E Psychedelic Stocks Index -6.2% This Week Vs. +18.7% And +35.3% The Previous Two Weeks

NOTE: The 3 largest psychedelic drug stocks in the sector were down 5.3% for the week ending Thursday compared to -1.5% the previous week. They are not included in the Index because they either trade in excess of $2/share and/or have a market cap in excess of $200M, since their inclusions would make a comparative analysis and Index averages meaningless. For the record, below are their performances for the week ending Thursday with the previous week's performances in brackets:

  1. Compass (CMPS) -3.4% (-0.07%)
  2. Field Trip (FTRPF) -20.5% (+12.0%)
  3. MindMed (MMEDF) -16.2(+1.4%)

The remaining 13 stocks in this fledgling, yet burgeoning, sector were down -1.6%, on average, for the week ending Thursday compared to +7.8% the previous week. They are not eligible for inclusion in the munKNEE Psychedelic Stocks Index but are worth watching closely (see a previous article on the subject here) with the sector starting to gain considerable traction. They are as follows:

Aion (CSE: AION), Codebase (BKLLF), Ehave (EHVVF), Graph Blockchain  (REGRF), Lobe Sciences (GTSIF), New Wave (TRMNF), Thoughtful Brands (PEMTF), Entheon (ENTBF), Core One (CLABF), Newscope-PharmaTher (CSE: PHRM), Nutritional High (SPLIF), Pure Extracts (CSE: PULL) and Tryp Therapeutics (CSE: TRYP).

Please note that Minerco (MINE) has been removed from the list as it is trading below $0.01/share on very spotty volume and Tryp Therapeutics (CSE: TRYP), which was listed earlier this month, has been added.

1 2
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.